This Article Abstract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Du, X.-J. Articles by Dart, A. M. Search for Related Content PubMed PubMed Citation Articles by Du, X.-J. Articles by Dart, A. M.

(Circulation. 1995;91:2712-2716.)
© 1995 American Heart Association, Inc.

Articles

Suppression of Ventricular Arrhythmias During Ischemia-Reperfusion by Agents Inhibiting Ins(1,4,5)P₃ Release

Xiao-Jun Du, MB, PhD; Karen E. Anderson, BSc; Alexander Jacobsen, BSc, MBBS; Elizabeth A. Woodcock, PhD; Anthony M. Dart, MRCP, PhD

From the Alfred and Baker Medical Unit and Cellular Biochemistry Laboratory, Alfred Hospital and Baker Medical Research Institute, Melbourne, Australia.

Correspondence to Dr Anthony Dart, Alfred and Baker Medical Unit, Baker Medical Research Institute, Commercial Rd, Prahran (Melbourne), Victoria 3181, Australia.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background Reperfusion following myocardial ischemia causes a rapid and transient release of inositol (1,4,5)triphosphate [Ins(1,4,5)P₃]. The aim of this study was to test whether this increased Ins(1,4,5)P₃ release was important for the development of ventricular arrhythmias and whether agents that inhibit this signal transduction pathway, such as aminoglycoside antibiotics, suppress arrhythmias.

Methods and Results In perfused rat hearts, ventricular tachycardia (VT), ventricular fibrillation (VF), and accumulation of Ins(1,4,5)P₃ were measured during early reperfusion. A number of different compounds, including neomycin, gentamicin, streptomycin, spermine, reserpine, and prazosin, were effective in inhibiting the reperfusion-induced Ins(1,4,5)P₃ release and the onset of VT and VF in parallel. A strong correlation existed between Ins(1,4,5)P₃ content, measured at 2 minutes of reperfusion, and the incidence of reperfusion VT and VF. In addition, intravenous gentamicin suppressed the onset of arrhythmias under ischemic and reperfusion conditions in vivo.

Conclusions Our results are consistent with the view that Ins(1,4,5)P₃ release plays a pivotal role in mediating arrhythmias during early reperfusion. Agents inhibiting Ins(1,4,5)P₃ release are antiarrhythmic and may have potential use clinically.

Key Words: arrhythmia • ischemia • reperfusion

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
In cardiac tissue, inositol (1,4,5)triphosphate [Ins(1,4,5)P₃] has been shown to cause a slow release of Ca²⁺, which is associated with activation of Na⁺-Ca²⁺ exchange and Ca²⁺ oscillation.^{1 2} Activation of ₁-adrenoceptors was demonstrated during postischemic reperfusion,³ and recently an enhanced release of Ins(1,4,5)P₃ was also shown to occur.⁴ Oscillations of intracellular Ca²⁺ are known to be arrhythmogenic.⁵ These findings raise the possibility that release of Ins(1,4,5)P₃ might initiate and facilitate arrhythmias and thus that inhibition of this release might prove to be antiarrhythmic. Aminoglycoside antibiotics and spermine were shown to inhibit Ins(1,4,5)P₃ release by binding to its precursor phosphatidylinositol (4,5)biphosphate in many tissues,^{6 7 8} and we recently reported an enhanced potency of neomycin in inhibiting Ins(1,4,5)P₃ release under conditions of postischemia reperfusion.⁴ However, no studies have tested whether other aminoglycosides have similar inhibitory effects on Ins(1,4,5)P₃ release during reperfusion or on whether such interventions are antiarrhythmic.

Thus, the present study was undertaken to examine the effects of aminoglycosides neomycin, gentamicin, streptomycin, and spermine on reperfusion-induced ventricular arrhythmias and Ins(1,4,5)P₃ release in perfused rat hearts. To evaluate the potential significance of these findings, the antiarrhythmic activity of gentamicin was further investigated in intact animals.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Animals and Agents
Male Sprague-Dawley rats (200 to 350 g) were anesthetized with pentobarbital (60 mg/kg IP) when required. The following agents were used: neomycin (Alfred Hospital pharmacy), gentamicin (Delta West), streptomycin (Servipharm), propranolol (Sigma Chemical Co.), lithium chloride (LiCl, Sigma), reserpine (Sigma), prazosin (Pfizer), spermine (Calbiochem), staurosporine (Boehringer Mannheim), and assay kits for Ins(1,4,5)P₃ measurement (Amersham).

Mass Analysis of Ins(1,4,5)P₃ in Isolated Perfused Hearts
The methods used to measure the myocardial content of Ins(1,4,5)P₃ were as described previously in detail.⁴ In brief, isolated hearts were perfused through the aorta at 5 mL · g^-1 · min^-1 with HEPES-buffered Krebs' medium (37°C) according to the Langendorff procedure. The medium contained (mmol/L) Na⁺ 138, K⁺ 5.9, Ca²⁺ 2.0, Mg²⁺ 1.2, HCO₃^- 25, PO₄^3- 1.2, HEPES 20, and glucose 11 and was equilibrated with 95% O₂/5% CO₂ (pH 7.4). Global ischemia was produced when perfusion was stopped for 20 minutes, and reperfusion was produced when flow was reinitiated. Propranolol (1 µmol/L), LiCl (50 mmol/L with the concentration of Na⁺ reduced accordingly), and investigational agents were added to the medium 10 minutes before ischemia and maintained throughout the remainder of the ischemia-reperfusion protocol.⁴ We ended the experiment by freezing the heart in liquid nitrogen either immediately before reperfusion or 2 minutes after reperfusion. A reperfusion period of 2 minutes was chosen because our previous studies showed that the enhanced release of Ins(1,4,5)P₃ was maximal at this time.⁴ Ins(1,4,5)P₃ was extracted in 3.5 mL of 5% trichloroacetic acid containing 2.5 mmol/L EDTA and 5 mmol/L ATP, as previously described in detail.⁴ Ins(1,4,5)P₃ mass was measured with Amersham assay kits and expressed as picomoles per milligram of protein.⁴

Preparations and Protocols for Arrhythmia Experiments
Arrhythmia Experiments In Vitro
Experiments were performed in rat hearts perfused in situ at approximately 5 mL · g^-1 · min^-1 with Krebs-Henseleit solution at 37°C.⁹ The perfusate contained (mmol/L) Na⁺ 145, K⁺ 4.0, Ca²⁺ 1.85, Mg^2- 1.05, HCO₃^- 25, PO₄^3- 0.5, glucose 11, and EDTA 0.027 and was constantly gassed with O₂-CO₂ (95%-5%, pH 7.4). Regional ischemia was produced by occlusion of the left coronary artery about 3 mm from its origin with subsequent release to allow reperfusion. The perfusion flow rate was adjusted coincidently with coronary occlusion or reperfusion to maintain a constant perfusion pressure. Epicardial ECG, perfusion pressure, and in some preparations, left ventricular pressure were recorded on a Grass polygraph.⁹

In all experiments, drug or vehicle infusion was started 10 minutes before coronary occlusion and then was maintained throughout the remainder of the ischemia-reperfusion protocol. A 20-minute ischemic period was used, followed by a 5-minute reperfusion period. The ECG was monitored during the ischemic period and for 5 minutes after reperfusion to ensure that the development of arrhythmias was inhibited rather than postponed by the agents tested. Ventricular arrhythmias, ie, ventricular premature beats (VPB), tachycardia (VT), and fibrillation (VF), were measured during the 5-minute reperfusion period and defined and analyzed according to the guidelines of the Lambeth Conventions.¹⁰ All experiments were performed in the presence of propranolol (1 µmol/L) and LiCl (10 mmol/L). The incidence of ischemic VT and VF was reduced significantly by treatment with propranolol to 40% and 30%, respectively, compared with 80% and 75% in control group (both P<.05) but was unaffected by LiCl (70% and 60%, respectively). The incidence of reperfusion arrhythmias was unaffected by either single agent (100% and 86% versus 67% for VT; 72% and 71% versus 67% for VF) or a combination of agents. In view of the effect of propranolol on ischemic arrhythmias, analysis was limited to reperfusion for the in vitro experiments.

Arrhythmia Experiments In Vivo
An anesthetized, ventilated, and open-chest rat model was used to test the effect of gentamicin on ventricular arrhythmias during regional ischemia and reperfusion in vivo.¹¹ The right carotid artery was cannulated with a Millar microtipped transducer catheter to measure arterial blood pressure. A loose ligature was positioned around the left coronary artery for subsequent occlusion. The ischemic period was 10 minutes, followed by reperfusion for 5 minutes. We found 10 minutes to be the optimal ischemic period for the development of reperfusion arrhythmias in this model. Gentamicin infusion, at either 2.5 or 7.5 mg · kg^-1 · min^-1, began 10 minutes before the onset of ischemia and continued for the remainder of the experiment. In hearts without irreversible VF, the coronary artery was reoccluded at the end of the experiment, and the ischemic area was measured by a dye method and expressed as percentages of the total ventricular weight. Arrhythmias were defined and analyzed according to the Lambeth Conventions.¹⁰

Statistics
The ² test with Fisher's exact calculation was used to estimate the significance of differences in the incidence of VT and VF between control and drug-treated groups. Comparison for the difference in frequencies of VPB was performed by the Mann-Whitney test. The significance of differences for all other comparisons was determined with paired or unpaired Student's t test, with results presented as mean±SEM. The least-squares method was used for linear correlation and regression between mass content of Ins(1,4,5)P₃ and incidence of arrhythmias.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Ins(1,4,5)P₃ Content in Perfused Hearts During Reperfusion
The mass content of Ins(1,4,5)P₃ in rat ventricles after 20 minutes of global ischemia was 103±18 pmol/mg protein (mean±SEM, n=4). This increased during 2 minutes of reperfusion with oxygenated medium to 207±11 pmol/mg (P<.01). The aminoglycosides neomycin, gentamicin, and streptomycin at concentrations of 0.015 to 5 mmol/L produced dose-dependent inhibition of the reperfusion-induced release of Ins(1,4,5)P₃. Spermine (5 mmol/L), reserpine (5 mg/kg by IP injection 18 hours before experimentation), and prazosin (10 µmol/L) also inhibited Ins(1,4,5)P₃ release at 2 minutes of reperfusion (Table 1).

View this table: [in this window] [in a new window]   Table 1. Effects of Inhibitors on the Incidence of Ventricular Arrhythmias During 5 Minutes of Reperfusion After 20 Minutes of Regional Ischemia in Hearts Perfused In Situ and on Mass Content of Ins(1,4,5)P3 Measured at 2 Minutes of Reperfusion After 20 Minutes of Global Ischemia in Isolated Perfused Rat Hearts

Reperfusion Arrhythmias in Perfused Hearts
There was no significant difference in the incidence of reperfusion arrhythmias between control groups from the different experiments; therefore, combined data from 64 control rats were used. All three aminoglycosides tested suppressed reperfusion VPB, VT, and VF in a dose-dependent manner (Table 1). Spermine 5 mmol/L was also antiarrhythmic. To further establish the role of norepinephrine and ₁-adrenoceptors in mediating reperfusion arrhythmias, other agents were tested. Interventions that depleted cardiac norepinephrine (reserpine) or blocked ₁-adrenoceptors (prazosin) also reduced the incidence of reperfusion arrhythmias (Table 1). On the other hand, staurosporine at a concentration known to be effective in inhibiting protein kinase C (PKC) in perfused rat hearts¹² did not inhibit reperfusion VT and VF, although the frequency of VPB was reduced. This indicates that the activation of PKC by 1,2-diacylglycerol released coincidently with Ins(1,4,5)P₃¹³ is not important in inducing severe reperfusion arrhythmias. All agents that inhibited Ins(1,4,5)P₃ release were also effective in suppressing reperfusion arrhythmias. A strong correlation was observed between tissue Ins(1,4,5)P₃ levels and the incidence of VPB, VT, and VF during reperfusion (Figure).

View larger version (11K): [in this window] [in a new window]   Figure 1. Graphs showing correlation between inositol (1,4,5)triphosphate [Ins(1,4,5)P3] content in the ventricles and the incidence of ventricular premature beats (VPB), ventricular tachycardia (VT), and ventricular fibrillation (VF) during reperfusion in perfused rat hearts subjected to 20 minutes of ischemia. Ins(1,4,5)P3 results (means of four measurements in each group) were obtained in isolated perfused hearts subjected to global ischemia, with Ins(1,4,5)P3 measured at 2 minutes of reperfusion. Arrhythmia experiments were performed in in situ perfused rat hearts subjected to regional ischemia with monitoring of arrhythmias during a 5-minute period of reperfusion. Table 1 also shows all the data.

Ischemic and Reperfusion Arrhythmias In Vivo
Coronary artery occlusion induced high incidences of ischemic VPB, VT, and VF in control rats that were reduced by intravenous gentamicin in a dose-dependent manner (Table 2). Sustained VF occurred in 30% of control rats but in only 10% and 0% of rats receiving gentamicin at 2.5 and 7.5 mg · kg^-1 · min^-1, respectively.

View this table: [in this window] [in a new window]   Table 2. Frequency of Ventricular Arrhythmias During a 10-Minute Period of Coronary Artery Occlusion and the Following 5-Minute Reperfusion Period in Anesthetized, Ventilated, and Open-Chest Rats In Vivo

In 13 control rats that did not have sustained VF, reperfusion was performed after 10 minutes of ischemia. All control rats developed VT, and 69% developed VF during early reperfusion. These reperfusion-mediated arrhythmias were inhibited by gentamicin at 7.5 mg · kg^-1 · min^-1 but not at 2.5 mg · kg^-1 · min^-1 (Table 2).

There was no significant difference between groups in the size of ischemic area as a percentage of total ventricular weight (38.1±1.5% and 38.0±3.3% versus 34.9±2.8%).

Effects of Aminoglycosides on Cardiovascular Function In Vitro and In Vivo
In in situ perfused hearts, heart rate (HR) was unchanged by aminoglycosides at concentrations <1 mmol/L but reduced at the high concentration (data not shown). The pressure developed by contraction of the left ventricle (LVDevP) did not differ between groups and was constant during the stabilizing period (between 30 and 50 mm Hg). At the end of the 10-minute infusion with gentamicin 1.5 mmol/L, LVDevP was reduced to 45±7% of pretreatment values. However, LVDevP was well maintained in hearts treated with gentamicin at two lower doses (110±6% and 96±3% of control, respectively). Neomycin and streptomycin produced very similar effects on LVDevP compared with gentamicin.

In intact rats, infusion of gentamicin 7.5 mg · kg^-1 · min^-1 for 10 minutes reduced HR (from 429±11 to 374±14 beats per minute [bpm], P<.05) and mean arterial pressure (MAP, from 120±4 to 92±7 mm Hg, P<.05). Infusion with gentamicin 2.5 mg · kg^-1 · min^-1 caused only mild reductions in HR and MAP (443±6 to 428±5 bpm and 113±2 to 100±3 mm Hg, both P<.05). At the end of 10 minutes of ischemia, HR remained significantly lower in treated rats compared with untreated rats only in the high-dose group (355±12 and 422±15 versus 439±11 bpm). MAP was lower in both treated groups compared with controls (79±5 and 81±5 versus 107±6 mm Hg, both P<.05).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Previous in vitro experiments have shown that reperfusion after a period of global ischemia caused a rapid and transient release of Ins(1,4,5)P₃ in rat ventricles.⁴ This release depended on local release of norepinephrine and was mediated by ₁-adrenoceptors.⁴ In the current study, the importance of this pathway in initiating reperfusion arrhythmias was investigated by use of agents that inhibited this pathway at various stages. Agents that prevented release of norepinephrine or blocked ₁-adrenoceptors were shown to prevent reperfusion arrhythmias. In addition, the aminoglycosides neomycin, gentamicin, streptomycin, and spermine, which inhibited Ins(1,4,5)P₃ release, were effective antiarrhythmic agents. Such inhibitory effects of aminoglycosides on both Ins(1,4,5)P₃ release and arrhythmias were dose dependent. Most importantly, a high degree of correlation has been demonstrated between Ins(1,4,5)P₃ release and the incidence of VPB, VT, and VF during reperfusion. The correlation is surprisingly strong, considering the variability of arrhythmia indexes in this model and that the two parameters were obtained from independent experiments. Thus, these findings provide strong evidence that the release of Ins(1,4,5)P₃ is instrumental in initiating reperfusion arrhythmias under these conditions.

Gentamicin, the most effective agent in vitro, was also very effective in vivo in suppressing ischemic and reperfusion arrhythmias. It remains to be established whether the effect of gentamicin in vivo is also due to inhibition of Ins(1,4,5)P₃ release. While local norepinephrine release and -adrenoceptors are likely to be important in mediating arrhythmias in vivo,^{3 14 15 16} bloodborne factors, such as neutrophils or platelet-derived factors,^{17 18} are also likely to have important influences. Thus, ischemic and reperfusion arrhythmias in vivo may have more complex origins than those in our in vitro model. Furthermore, the degree of ischemia in vivo may not be uniform and thus may lead to differences in the pattern of inositol phosphate release. Studies currently under way in our laboratory demonstrate that while inositol phosphate content is decreased under conditions of global and severe ischemia, the response to norepinephrine remains intact under more moderate ischemic conditions. Thus, it is possible that under the less-defined conditions of ischemia in vivo, Ins(1,4,5)P₃ has a role in the development of arrhythmias during early ischemia and reperfusion. Studies by Anyukhovsky and coworkers¹⁹ showed a pivotal role of ₁-adrenoceptors in mediating the onset of "ischemic arrhythmias" in Purkinje fibers incubated under conditions of simulated moderate ischemia.

The intracellular events following Ins(1,4,5)P₃ release have not been examined in this study. In normoxic cardiac tissues, ₁-adrenergic stimulation has no proarrhythmic effect.^{3 19} ₁-Agonists, however, are arrhythmogenic in cardiac preparations exposed to ischemic (or hypoxic) and reperfusion conditions.^{3 19 20} The electrophysiological changes induced by ₁-stimulation include potentiated abnormal automaticity, enhanced afterdepolarizations and triggered activity, and prolonged action potential duration, which favors reentry.²¹ The intracellular events leading to these changes are most probably increased and oscillating levels of intracellular calcium.⁵ In most cell types, addition of Ins(1,4,5)P₃ causes a rapid and transient release of Ca²⁺.²² The heart is relatively insensitive to Ins(1,4,5)P₃, which causes a slow release of calcium.¹ However, Ins(1,4,5)P₃ was reported to enhance calcium oscillations in myocardial preparations.² Furthermore, while norepinephrine stimulation does not increase Ins(1,4,5)P₃ in normoxic hearts,²³ reperfusion is associated with marked stimulation.⁴ It is of interest that the sensitivity of Ins(1,4,5)P₃ receptors is enhanced under conditions of oxidizing stress or increased intracellular Ca²⁺,^{24 25 26} situations pertaining during ischemia-reperfusion.²⁷ This raises the possibility that in addition to enhanced Ins(1,4,5)P₃ release under reperfusion conditions, the response to Ins(1,4,5)P₃ is also potentiated. These speculations remain to be investigated.

The present study, together with other recent findings,⁴ provides evidence for a pivotal role of Ins(1,4,5)P₃ in the genesis of reperfusion arrhythmias and perhaps of ischemic arrhythmias in vivo. These findings potentially have important clinical implications because not only catecholamines but also other factors such as thrombin, angiotensin II, endothelin, and mechanical stretch^{28 29 30} stimulate Ins(1,4,5)P₃ formation in the heart, and many of these factors are found to be present under pathological conditions such as myocardial ischemia and reperfusion and heart failure. Agents that interfere with Ins(1,4,5)P₃ release may prove to be effective clinically, constituting a new approach in antiarrhythmic drug therapy.

	Acknowledgments

 
This study was supported by grants from the National Health and Medical Research Council, Australia, the Australian National Heart Foundation, and the Alfred Hospital Research Fund (Z9407). K.E.A. is the recipient of a Dora Lush biochemical postgraduate scholarship. A.J. is the recipient of a medical postgraduate scholarship from the National Heart Foundation.

Received February 9, 1995; revision received March 15, 1995; accepted March 27, 1995.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Kentish JC, Barsotti RJ, Lea TJ, Mulligan IP, Patel JR, Ferenczi MA. Calcium release from cardiac sarcoplasmic reticulum induced by photorelease of calcium or Ins(1,4,5)P₃. Am J Physiol. 1990;258:H610-H615. [Abstract/Free Full Text]
   
2. Zhu Y, Nosek TM. Inositol trisphosphate enhances Ca²⁺ oscillations but not Ca²⁺-induced Ca²⁺ release from cardiac sarcoplasmic reticulum. Pflugers Arch. 1991;418:1-6. [Medline] [Order article via Infotrieve]
   
3. Sheridan DJ, Penkoske PA, Sobel BE. -Adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats. J Clin Invest. 1980;65:161-171.
   
4. Anderson KE, Dart AM, Woodcock EA. Inositol phosphate release and metabolism during myocardial ischemia and reperfusion in the rat heart. Circ Res. 1995;76:261-268. [Abstract/Free Full Text]
   
5. Levy MN. Role of calcium in arrhythmogenesis. Circulation. 1989;80(suppl IV):IV-23-IV-30.
   
6. Gabev E, Kasianowicz J, Abbott T, McLaughlin S. Binding of neomycin to phosphatidylinositol 4,5-bisphosphate (PIP₂). Biochim Biophys Acta. 1989;979:105-112. [Medline] [Order article via Infotrieve]
   
7. Ramsammy LS, Josepovitz C, Kaloyanides GJ. Gentamicin inhibits agonist stimulation of the phosphatidylinositol cascade in primary cultures of rabbit proximal tubular cells and in rat renal cortex. J Pharmacol Exp Ther. 1988;247:989-996. [Abstract/Free Full Text]
   
8. Cooper CL, Holz RW. Neomycin and spermine have similar effects on secretion and phosphoinositide metabolism in ATP-depleted permeabilized adrenal chromaffin cells. Biochem Biophys Res Commun. 1993;194:1135-1142. [Medline] [Order article via Infotrieve]
   
9. Du X-J, Riemersma RA, Fox KAA, Dart AM. Propranolol and lidocaine inhibit neural norepinephrine release in hearts with increased extracellular potassium and ischemia. Circulation. 1993;88:1885-1892. [Abstract/Free Full Text]
   
10. Walker MJA, Curtis MJ, Hearse DJ, Campbell RWF, Janse MJ, Yellon DM, Cobbe SM, Coker SJ, Harness JB, Harron DWG, Higgins AJ, Julian DG, Lab MJ, Manning AS, Northover BJ, Parratt JR, Riemersma RA, Riva E, Russell DC, Sheridan DJ, Winslow E, Woodward B. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia, infarction, and reperfusion. Cardiovasc Res. 1988;22:447-455. [Medline] [Order article via Infotrieve]
    
11. Curtis MJ, Macleod BA, Walker MJA. Models for the study of arrhythmias in myocardial ischaemia and infarction: the use of the rat. J Mol Cell Cardiol. 1987;19:399-419.[Medline] [Order article via Infotrieve]
    
12. Strasser RH, Braun-Dullaeus R, Walendzik H, Marquetant R. ₁-Receptor independent activation of protein kinase C in acute myocardial ischemia. Circ Res. 1992;70:1304-1312. [Abstract/Free Full Text]
    
13. Kawai T, Okumura K, Hashimoto H, Ito T, Satake T. Alteration of 1,2-diacylglycerol content in ischemic and reperfusion heart. Mol Cell Biochem. 1990;99:1-8. [Medline] [Order article via Infotrieve]
    
14. Forfar JC, Russell DC, Riemersma RA. Control of myocardial catecholamine release during acute ischemia. J Cardiovasc Pharmacol. 1985;7(suppl 5):S33-S39.
    
15. Franco-Cereceda A, Owall A, Settergren G, Sollevi A, Lundberg JM. Release of neuropeptide Y and noradrenaline from the human heart after aortic occlusion during coronary artery surgery. Cardiovasc Res. 1990;24:242-246. [Abstract/Free Full Text]
    
16. Schwartz PJ, Zuanetti G. Role of the autonomic nervous system in reperfusion arrhythmias. J Mol Cell Cardiol. 1988;20(suppl II):113-118.
    
17. Lucchesi BR. Modulation of leukocyte-mediated myocardial reperfusion injury. Annu Rev Physiol. 1990;52:561-576. [Medline] [Order article via Infotrieve]
    
18. Goldstein JA, Butterfield MC, Ohnishi Y, Shelton TJ, Corr PB. Arrhythmogenic influence of intracoronary thrombosis during acute myocardial ischemia. Circulation. 1994;90:139-147. [Abstract/Free Full Text]
    
19. Anyukhovsky EP, Steinberg SF, Cohen IS, Rosen MR. Receptor-effector coupling pathway for ₁-adrenergic modulation of abnormal automaticity in `ischemic' canine Purkinje fibers. Circ Res. 1994;74:937-944. [Abstract/Free Full Text]
    
20. Kawana S, Kimura H, Miyamoto A, Ohshika H, Namiki A. ₁-Adrenoceptors in neonatal rat cardiac myocytes: hypoxia alters the responsiveness of _1A and _1B subtypes. Life Sci. 1993;53:411-416.
    
21. Gettes LS, Cascio WE. Effect of acute ischemia on cardiac electrophysiology. In: Forzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, eds. The Heart and Cardiovascular System: Scientific Foundations. New York, NY: Raven Press; 1991:2021-2054.
    
22. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature. 1993;361:315-325. [Medline] [Order article via Infotrieve]
    
23. Woodcock EA, Suss MB, Anderson KE. Inositol phosphate release and metabolism in rat left atria. Circ Res. 1995;76:252-260. [Abstract/Free Full Text]
    
24. Bird GSJ, Burgess GM, Putney JW Jr. Sulfhydryl reagents and cAMP-dependent kinase increase the sensitivity of the inositol 1,4,5-trisphosphate receptor in hepatocytes. J Biol Chem. 1993;268:17917-17923. [Abstract/Free Full Text]
    
25. Hilly M, Pietri-Rouxel F, Coquil JF, Guy M, Mauger JP. Thiol reagents increase the affinity of the inositol 1,4,5-trisphosphate receptor. J Biol Chem. 1993;268:16488-16494. [Abstract/Free Full Text]
    
26. Missiaen L, De Smedt H, Parys JB, Casteels R. Co-activation of inositol trisphosphate-induced Ca²⁺ release by cytosolic Ca²⁺ is loading-dependent. J Biol Chem. 1994;269:7238-7242. [Abstract/Free Full Text]
    
27. Tani M. Mechanisms of Ca²⁺ overload in reperfused ischemic myocardium. Annu Rev Physiol. 1990;52:543-559. [Medline] [Order article via Infotrieve]
    
28. Chien WW, Mohabir R, Clusin WT. Effect of thrombin on calcium homeostasis in chick embryonic heart cells: receptor-operated calcium entry with inositol trisphosphate and a pertussis toxin-sensitive G protein as second messengers. J Clin Invest. 1990;85:1436-1443.
    
29. Kuraja IJ, Tanner JK, Woodcock EA. Endothelin stimulates phosphatidylinositol turnover in rat left and right atria. Eur J Pharmacol. 1990;189:299-306. [Medline] [Order article via Infotrieve]
    
30. von Harsdorf R, Lang RE, Fullerton M, Woodcock EA. Myocardial stretch stimulates phosphatidylinositol turnover. Circ Res. 1989;65:494-501.[Abstract/Free Full Text]
    

This article has been cited by other articles:

				E. A. Woodcock, X.-J. Du, M. E. Reichelt, and R. M. Graham Cardiac {alpha}1-adrenergic drive in pathological remodelling Cardiovasc Res, February 1, 2008; 77(3): 452 - 462. [Abstract] [Full Text] [PDF]

				A. A. Lanzafame, L. Turnbull, F. Amiramahdi, J. F. Arthur, H. Huynh, and E. A. Woodcock Inositol phospholipids localized to caveolae in rat heart are regulated by {alpha}1-adrenergic receptors and by ischemia-reperfusion Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2059 - H2065. [Abstract] [Full Text] [PDF]

				X. Li, A. V. Zima, F. Sheikh, L. A. Blatter, and J. Chen Endothelin-1-Induced Arrhythmogenic Ca2+ Signaling Is Abolished in Atrial Myocytes of Inositol-1,4,5-Trisphosphate(IP3)-Receptor Type 2-Deficient Mice Circ. Res., June 24, 2005; 96(12): 1274 - 1281. [Abstract] [Full Text] [PDF]

				E. A. Woodcock, B. H. Wang, J. F. Arthur, A. Lennard, S. J. Matkovich, X.-J. Du, J. H. Brown, and R. D. Hannan Inositol Polyphosphate 1-Phosphatase Is a Novel Antihypertrophic Factor J. Biol. Chem., June 14, 2002; 277(25): 22734 - 22742. [Abstract] [Full Text] [PDF]

				G. Vassort Adenosine 5'-Triphosphate: a P2-Purinergic Agonist in the Myocardium Physiol Rev, April 1, 2001; 81(2): 767 - 806. [Abstract] [Full Text] [PDF]

				F. Duru, M. Barton, T. F. Luscher, and R. Candinas Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? Cardiovasc Res, February 1, 2001; 49(2): 272 - 280. [Abstract] [Full Text] [PDF]

				S. J. Matkovich and E. A. Woodcock Ca2+-activated but Not G Protein-mediated Inositol Phosphate Responses in Rat Neonatal Cardiomyocytes Involve Inositol 1,4,5-Trisphosphate Generation J. Biol. Chem., April 6, 2000; 275(15): 10845 - 10850. [Abstract] [Full Text] [PDF]

				A. Gysembergh, S. Lemaire, C. Piot, C. Sportouch, S. Richard, R. A. Kloner, and K. Przyklenk Pharmacological manipulation of Ins(1,4,5)P3 signaling mimics preconditioning in rabbit heart Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2458 - H2469. [Abstract] [Full Text] [PDF]

				X.-J. Du and A. M. Dart Role of sympathoadrenergic mechanisms in arrhythmogenesis Cardiovasc Res, September 1, 1999; 43(4): 832 - 834. [Full Text] [PDF]

				E. Carmeliet Cardiac Ionic Currents and Acute Ischemia: From Channels to Arrhythmias Physiol Rev, July 1, 1999; 79(3): 917 - 1017. [Abstract] [Full Text] [PDF]

				K. PRZYKLENK, B. Z. SIMKHOVICH, B. BAUER, K. HATA, L. ZHAO, G. T. ELLIOTT, and R. A. KLONER Cellular Mechanisms of Infarct Size Reduction with Ischemic Preconditioning: Role of Calcium? Ann. N.Y. Acad. Sci., June 30, 1999; 874(1): 192 - 210. [Abstract] [Full Text] [PDF]

				T. Kurz, I. Schneider, R. Tolg, and G. Richardt Alpha1-adrenergic receptor-mediated increase in the mass of phosphatidic acid and 1,2-diacylglycerol in ischemic rat heart Cardiovasc Res, April 1, 1999; 42(1): 48 - 56. [Abstract] [Full Text] [PDF]

				E. Hatta, R. Maruyama, S. J. Marshall, M. Imamura, and R. Levi Bradykinin Promotes Ischemic Norepinephrine Release in Guinea Pig and Human Hearts J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 919 - 927. [Abstract] [Full Text]

				E. A. Woodcock, N. Reyes, A. N. Jacobsen, and X.-J. Du Inhibition of Inositol(1,4,5)Trisphosphate Generation by Endothelin-1 During Postischemic Reperfusion : A Novel Antiarrhythmic Mechanism Circulation, February 16, 1999; 99(6): 823 - 828. [Abstract] [Full Text] [PDF]

				S. N. Harrison, D. J. Autelitano, B. H. Wang, C. Milano, X.-J. Du, and E. A. Woodcock Reduced Reperfusion–Induced Ins(1,4,5)P3 Generation and Arrhythmias in Hearts Expressing Constitutively Active {alpha}1B-Adrenergic Receptors Circ. Res., December 14, 1998; 83(12): 1232 - 1240. [Abstract] [Full Text] [PDF]

				E. A Woodcock, S. J Matkovich, and O. Binah Ins(1,4,5)P3 and cardiac dysfunction Cardiovasc Res, November 1, 1998; 40(2): 251 - 256. [Full Text] [PDF]

				M. J Curtis Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation Cardiovasc Res, July 1, 1998; 39(1): 194 - 215. [Abstract] [Full Text] [PDF]

				B. Felzen, M. Shilkrut, H. Less, I. Sarapov, G. Maor, R. Coleman, R. B. Robinson, G. Berke, and O. Binah Fas (CD95/Apo-1)–Mediated Damage to Ventricular Myocytes Induced by Cytotoxic T Lymphocytes From Perforin-Deficient Mice : A Major Role for Inositol 1,4,5-Trisphosphate Circ. Res., March 9, 1998; 82(4): 438 - 450. [Abstract] [Full Text] [PDF]

				Y. Watanabe, T. Ishigami, Y. Kawano, T. Umahara, A. Nakamori, S. Mizushima, K. Hibi, I. Kobayashi, K. Tamura, H. Ochiai, et al. Angiotensin-Converting Enzyme Gene I/D Polymorphism and Carotid Plaques in Japanese Hypertension, September 1, 1997; 30(3): 569 - 573. [Abstract] [Full Text]

				A. N. Jacobsen, X.-J. Du, K. A. Lambert, A. M. Dart, and E. A. Woodcock Arrhythmogenic Action of Thrombin During Myocardial Reperfusion via Release of Inositol 1,4,5-Triphosphate Circulation, January 1, 1996; 93(1): 23 - 26. [Abstract] [Full Text]

				J. F. Arthur, S. J. Matkovich, C. J. Mitchell, T. J. Biden, and E. A. Woodcock Evidence for Selective Coupling of alpha 1-Adrenergic Receptors to Phospholipase C-beta 1 in Rat Neonatal Cardiomyocytes J. Biol. Chem., September 28, 2001; 276(40): 37341 - 37346. [Abstract] [Full Text] [PDF]

This Article Abstract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Du, X.-J. Articles by Dart, A. M. Search for Related Content PubMed PubMed Citation Articles by Du, X.-J. Articles by Dart, A. M.